Successful Use of Omalizumab in an Inadequately Controlled Type 2 Diabetic Patient With Severe Insulin Allergy
Open Access
- 11 May 2012
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (6) , e41
Abstract
A 62-year-old male patient with type 2 diabetes for 16 years developed a severe anaphylactic shock upon administration of intravenous, short-acting regular insulin. The patient’s medical history comprised allergic reactions to an unknown agent as a child as well as injection site reactions, urticaria, and dyspnea to subcutaneous NPH-insulin injections. The diagnostic work-up revealed a type 1 IgE-mediated insulin allergy by positive skin prick tests and elevated specific IgE levels against insulins of human, porcine, and bovine origin by ImmunoCAP-Assay. The insulins used were free of proinsulin. Skin prick tests with all solvents and additives of the insulin solutions were negative. Genetic sequencing of the patient’s insulin molecule revealed a normal insulin gene. Because of unsatisfactory glycemic control, specific desensitization (1) and maintenance therapy with insulin detemir was performed, but improvement of urticaria and …Keywords
This publication has 6 references indexed in Scilit:
- Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthmaJournal of Allergy and Clinical Immunology, 2010
- Rituximab and Omalizumab in Severe, Refractory Insulin AllergyNew England Journal of Medicine, 2009
- Insulin allergy: clinical manifestations and management strategiesAllergy, 2008
- ReplyJournal of Allergy and Clinical Immunology, 2007
- Omalizumab for drug allergyJournal of Allergy and Clinical Immunology, 2007
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004